These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37789128)

  • 21. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
    Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
    Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing future fractures: effectiveness of an orthogeriatric fracture liaison service compared to an outpatient fracture liaison service and the standard management in patients with hip fracture.
    Naranjo A; Fernández-Conde S; Ojeda S; Torres-Hernández L; Hernández-Carballo C; Bernardos I; Rodríguez S; Laynez P
    Arch Osteoporos; 2017 Dec; 12(1):112. PubMed ID: 29230540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary prevention of osteoporotic fractures: evaluation of the Lille University Hospital's Fracture Liaison Service between January 2016 and January 2018.
    Pflimlin A; Gournay A; Delabrière I; Chantelot C; Puisieux F; Cortet B; Paccou J
    Osteoporos Int; 2019 Sep; 30(9):1779-1788. PubMed ID: 31190123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice.
    Oswald AJ; Berg J; Milne G; Ralston SH
    Calcif Tissue Int; 2014 Feb; 94(2):176-82. PubMed ID: 24026567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries.
    Malik AT; Retchin S; Phillips FM; Xu W; Peters K; Yu E; Khan SN
    Spine J; 2020 Apr; 20(4):538-546. PubMed ID: 31683068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk.
    Degli Esposti L; Girardi A; Saragoni S; Sella S; Andretta M; Rossini M; Giannini S;
    Endocrine; 2019 May; 64(2):367-377. PubMed ID: 30515678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).
    Cunha-Borges JL; Mier GM; Casas N; Medina A; Molina JF; García ML; Oliveria LG; Caselato MS; Cruz AC; Ippolito V; Flórez S
    Adv Rheumatol; 2019 Nov; 59(1):46. PubMed ID: 31703737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fracture liaison services for osteoporosis in the Asia-Pacific region: current unmet needs and systematic literature review.
    Chang Y-; Huang C-; Hwang J-; Kuo J-; Lin K-; Huang H-; Bagga S; Kumar A; Chen F-; Wu C-
    Osteoporos Int; 2018 Apr; 29(4):779-792. PubMed ID: 29285627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD; Martineau P; Bryanton M; Lix LM
    Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orthopedic-Metabolic Collaborative Management for Osteoporotic Hip Fracture.
    Rotman-Pikielny P; Frankel M; Lebanon OT; Yaacobi E; Tamar M; Netzer D; Nabriski D; Nyska M; Brin YS
    Endocr Pract; 2018 Aug; 24(8):718-725. PubMed ID: 30084682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fracture liaison services combined with online home nursing care in fragility hip fracture: a comparative effectiveness pilot study.
    Lai H; Fan J; Liu H; Wu X; Wang L; Gao L; Zhou L; Chen T; Zhang L; Chen J; Luo Z
    Arch Osteoporos; 2023 Feb; 18(1):33. PubMed ID: 36809579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Danish, national cross-sectional observational study on the prevalence of prior major osteoporotic fractures in adults presenting with hip fracture-limitations and scope for fracture liaison services in prevention of hip fracture.
    Frederiksen A; Abrahamsen B; Johansen PB; Sørensen HA
    Osteoporos Int; 2018 Jan; 29(1):109-114. PubMed ID: 28965215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
    Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
    Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of a fracture liaison service--a real-world evaluation after 6 years of service provision.
    Yong JH; Masucci L; Hoch JS; Sujic R; Beaton D
    Osteoporos Int; 2016 Jan; 27(1):231-40. PubMed ID: 26275439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
    Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
    Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.